| scholarly article | Q13442814 |
| P2093 | author name string | Changgong Li | |
| Jiandong Chen | |||
| Lihong Chen | |||
| Yanhua Peng | |||
| Said Sebti | |||
| P2860 | cites work | Activation of an MDM2-specific caspase by p53 in the absence of apoptosis | Q40954121 |
| Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations | Q41037063 | ||
| Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study) | Q71845902 | ||
| Pharmacological rescue of mutant p53 conformation and function | Q73316566 | ||
| Mdm2 promotes the rapid degradation of p53 | Q24322597 | ||
| Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations | Q27730815 | ||
| Regulation of p53 stability by Mdm2 | Q27860744 | ||
| Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization | Q28212970 | ||
| The p53-mdm-2 autoregulatory feedback loop | Q28609811 | ||
| p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. | Q30428424 | ||
| Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 | ||
| Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy | Q34314426 | ||
| Elliptinium acetate in metastatic breast cancer--a phase II study | Q34645339 | ||
| Phase II study of elliptinium acetate salvage treatment of advanced breast cancer | Q34731136 | ||
| c-Myc target gene specificity is determined by a post-DNAbinding mechanism | Q36808429 | ||
| Correcting temperature-sensitive protein folding defects | Q37365357 | ||
| A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein | Q38313694 | ||
| Temperature-sensitive mutants of p53 homologs | Q40829936 | ||
| P433 | issue | 29 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4478-4487 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Rescue of mutant p53 transcription function by ellipticine | |
| P478 | volume | 22 |
| Q28534098 | A Novel Anticancer Agent, 8-Methoxypyrimido[4',5':4,5]thieno(2,3-b) Quinoline-4(3H)-One Induces Neuro 2a Neuroblastoma Cell Death through p53-Dependent, Caspase-Dependent and -Independent Apoptotic Pathways |
| Q37415505 | A global suppressor motif for p53 cancer mutants |
| Q35661403 | Assay strategies for identification of therapeutic leads that target protein trafficking |
| Q59049130 | BAY 61-3606, CDKi, and Sodium Butyrate Treatments Modulate p53 Protein Level and Its Site-Specific Phosphorylation in Human Vestibular SchwannomasIn Vitro |
| Q51578869 | CHIP chaperones wild type p53 tumor suppressor protein. |
| Q38845711 | CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo |
| Q38911627 | CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo |
| Q39812929 | Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition |
| Q38088759 | Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development |
| Q33642043 | Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. |
| Q28822335 | Chemical metabolic inhibitors for the treatment of blood-borne cancers |
| Q39104074 | Effects of ellipticine on ALDH1A1-expressing breast cancer stem cells--an in vitro and in silico study |
| Q38967701 | Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells |
| Q38988248 | Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage |
| Q39962477 | Ellipticine-induced apoptosis depends on Akt translocation and signaling in lung epithelial cancer cells |
| Q28077156 | Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness |
| Q35075365 | Escorts take the lead molecular chaperones as therapeutic targets |
| Q34385667 | Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein. |
| Q47962979 | ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathways. |
| Q57801891 | Inhibition of human Topoisomerase II by new N,N,N-trimethylethanammonium iodide alkylcarbazole derivatives |
| Q59237520 | Isolation, biological activity and synthesis of the natural product ellipticine and related pyridocarbazoles |
| Q33863319 | Karyotypic "state" as a potential determinant for anticancer drug discovery |
| Q38006988 | Molecular cytogenetic characterization of undifferentiated embryonal sarcoma of the liver: a case report and literature review |
| Q37034233 | Molecular modes of action of cytotoxic alkaloids: from DNA intercalation, spindle poisoning, topoisomerase inhibition to apoptosis and multiple drug resistance |
| Q33755827 | Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells |
| Q36766944 | Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73 |
| Q28483163 | Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine |
| Q37191174 | Pharmacological activation of p53 in cancer cells |
| Q30389604 | Pharmacological reactivation of mutant p53: from protein structure to the cancer patient |
| Q21131288 | Pharmacoperone Identification for Therapeutic Rescue of Misfolded Mutant Proteins |
| Q37893959 | Pro-senescence therapy for cancer treatment |
| Q35691573 | Regulating the p53 system through ubiquitination |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q24318162 | Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator |
| Q46814531 | Stimulation of suicidal erythrocyte death by ellipticine. |
| Q36430162 | Strategies for therapeutic targeting of the p53 pathway in cancer. |
| Q34317934 | Study of DNA-ellipticine interaction by capillary electrophoresis with laser-induced fluorescence detection. |
| Q37002735 | Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice |
| Q39286980 | Synthesis and biological evaluation of novel isoellipticine derivatives and salts |
| Q33655329 | Targeting p53 for Novel Anticancer Therapy |
| Q28593750 | The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions |
| Q91816686 | The Diverse Functions of Mutant 53, Its Family Members and Isoforms in Cancer |
| Q35016427 | The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes. |
| Q38870539 | The collective nuclear migration of p53 and phosphorylated S473 of Akt during ellipticine-mediated apoptosis in human lung epithelial cancer cells |
| Q35567279 | The role of p53 in chemosensitivity and radiosensitivity. |
| Q36422865 | The role of p73 in hematological malignancies |
| Q37081504 | The use of p53 as a tool for human cancer therapy |
| Q21089948 | Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs |
| Q38042630 | Therapeutic strategies for head and neck cancer based on p53 status |
| Q28755163 | Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease |
| Q35708113 | Translational approaches targeting the p53 pathway for anti-cancer therapy |
| Q37865050 | p53-targeted cancer pharmacotherapy: move towards small molecule compounds |
Search more.